For information on this past event please contact Meetings Management

Conference Program

Friday 12th October 2007

SESSION 8:
DNA VACCINES & ELECTROPORATION
Moderator: Eli Gilboa (University of Miami, USA)

08.30-09.00
‘Electroporation mediated delivery of DNA based cancer vaccines’
Drew Hannaman (ICHOR Medical Systems Inc., San Diego, California, USA)

09.00-09.20
‘In vivo electroporation for gene based immune therapy’
Iacob Mathieson (INOVIO, Oslo, Norway)

09.20-09.40
‘Enhanced immune responses to DNA vaccines via adaptive electroporation’
Niranjan Y. Sardesai (VGX Pharmaceuticals, USA)

09.40-10.00
‘DNA vaccines for treatment of cancer delivered by intradermal electroporation’
Anna-Karin Roos (Cancer Center Karolinska, Stockholm, Sweden/Cytopulse Inc., USA)

10.00-10.20
‘DNA vaccines that express laminin receptor protein fusions with chemoattractants elicit a long-term cytolytic T cell-mediated protection against syngeneic tumors’
Arya Biragyn (National Institutes of Health, Baltimore, Maryland, USA)

10.20-10.40
‘Gene gun-mediated vaccination followed by transfection with modified vaccinia virus vector expressing Rantes and hgp100 antigen drastically suppress melanoma metastasis’
K. Aravindaram, H.-H. Yu, C.-W. Lan, P.-H. Wang and N.S. Yang (Academia Sinica, Taipei, Taiwan, Republic of China)

10.40-11.00
Coffee & Posters

SESSION 9:
INDUSTRIAL VACCINES DEVELOPMENTS…
Moderator: John Samuel (University of Alberta, Edmonton, Canada)

11.00-11.30
‘Development of genetic vaccines for cancer’
Nicola La Monica (IRBM Merck, Rome, Italy)

11.30-12.00
‘GSK Biologicals AS04 adjuvanted cervical cancer candidate vaccine’
Marguerite Deschamps (GSK Biologicals, Rixensart, Belgium)

12.00-12.20
‘Recent clinical data with therapeutic cancer vaccines’
Jean-Yves Bonnefoy (Transgene SA, Strasbourg, France)

12.20-12.40
‘A cancer vaccine for gliobastoma – special case or example of a model for eventual success’
Robert F. Burns (Celldex Therapeutics Inc., Phillipsburg, New Jersey, USA)

12.40-14.00
Lunch & Posters

SESSION 10:
NEW VACCINES
Moderator: Viktor Umansky (DKFZ, Heidelberg, Germany)

14.00-14.30
‘Peptides for cancer vaccines’
Hans Georg Rammensee (University of Tubingen, Germany)

14.30-15.00
‘Dendritic cell vaccination: the quintessence after treating 200 melanoma patients with a standardized vaccine’
Gerold Schuler (University Hospital of Erlangen, Germany)

15.00-15.20
‘Correlation of T-cell response, clinical activity and regulatory T-cell levels in renal cell carcinoma patients treated with IMA901, a novel multi-peptide vaccine’
H. Sing-Jasuja, A. Mayer, S. Walter, T. Weinschenk, M. Staehler, P.Y. Dietrich, T. Eisen, A. Haferkamp, J. Beck, S. Stevanovic, H.G. Rammensee, A. Stenzl and J. Frisch (Immatics Biotechnologies GmbH, Tubingen, Germany)

15.20-15.40
‘ImmunoBodies a novel vaccine approach that stimulates high avidity CTL and helper T cell, anti-tumour immune responses’
V. Pudney, R. Metheringham, J.R. Ramage and L.G. Durrant (University of Nottingham, UK)

15.40-16.00
Tea & Poster Breakdown

16.00-16.20
‘Eradication of large tumors in mice by a tritherapy targeting the innate, adaptive and regulatory components of the immune system’
P. Berraondo, C. Nouze, X. Preville, D. Ladant and C. Leclerc (Institut Pasteur, Paris, France)

16.20-16.40
‘Tissue vaccines for prevention and treatment of prostate cancer’
M.A. Suckow, V.T. Sailes and W.R. Wolter (University of Notre Dame, Indiana, USA)

SESSION 11:
CLOSING PLENARY SESSION
Moderator: Volker Schirrmacher (DKFZ, Hedleberg, Germany)

16.40-17.10
‘Cancer vaccines: Where are we going from here?’
Eli Gilboa (University of Miami, USA)

17.10
Conference Close & Departure